Development of a New Class of Neuraminidase Inhibitors for the Treatment of Oseltamivir-Resistant Influenza and Other Circulating Influenza Strains

开发一类新型神经氨酸酶抑制剂，用于治疗奥司他韦耐药流感和其他循环流感病毒株

• 批准号: 200200
• 负责人: Brant Mike G
• 金额: $ 1.27万
• 依托单位: University of Victoria (British Columbia)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-02-01 至 2011-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=200200&lang=en
• 关键词: Antiviral Development; Drug Design; Influenza Treatment; Medicinal Chemistry; Neuraminidase Inhibitors; Organic Chemistry; Organic Synthesis; Synthetic Methodology

With the fear of a wide spread pandemic of influenza on the rise the need to develop new classes of antiviral drugs is of vital importance. Each year the influenza virus infects approximately 600 million people. 250,000-500,000 of these cases result in de

随着人们对流感大流行的恐惧不断增加，开发新型抗病毒药物的需求至关重要。每年流感病毒感染约6亿人。其中250，000 - 500，000例导致死亡